Marin H Kollef

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7502077/publications.pdf

Version: 2024-02-01

380 papers	42,099 citations	1883 102 h-index	2375 198 g-index
385 all docs	385 docs citations	385 times ranked	20624 citing authors

#	Article	IF	Citations
1	Inadequate Antimicrobial Treatment of Infections. Chest, 1999, 115, 462-474.	0.4	1,740
2	The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU Setting. Chest, 2000, 118, 146-155.	0.4	1,641
3	Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality. Antimicrobial Agents and Chemotherapy, 2005, 49, 3640-3645.	1.4	1,191
4	Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database. Chest, 2002, 122, 2115-2121.	0.4	1,089
5	Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Critical Care Medicine, 1999, 27, 2609-2615.	0.4	1,040
6	Epidemiology and Outcomes of Health-careâ€“Associated Pneumonia. Chest, 2005, 128, 3854-3862.	0.4	931
7	Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia. Chest, 2002, 122, 262-268.	0.4	912
8	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal, 2017, 50, 1700582.	3.1	792
9	A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. Critical Care Medicine, 1997, 25, 567-574.	0.4	743
10	Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?*. Critical Care Medicine, 2007, 35, 1257-1262.	0.4	724
11	The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections. Drugs, 2007, 67, 351-368.	4.9	710
12	Developing a New, National Approach to Surveillance for Ventilator-Associated Events*. Critical Care Medicine, 2013, 41, 2467-2475.	0.4	634
13	Linezolid vs Vancomycin *. Chest, 2003, 124, 1789-1797.	0.4	590
14	Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients. Clinical Infectious Diseases, 2000, 31, S131-S138.	2.9	553
15	Ventilator-Associated Pneumonia. JAMA - Journal of the American Medical Association, 1993, 270, 1965.	3.8	536
16	Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Critical Care Medicine, 2001, 29, 1109-1115.	0.4	536
17	The Influence of Mini-BAL Cultures on Patient Outcomes. Chest, 1998, 113, 412-420.	0.4	525
18	Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clinical Infectious Diseases, 2012, 54, 621-629.	2.9	513

#	Article	IF	Citations
19	Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center*. Critical Care Medicine, 2003, 31, 1312-1317.	0.4	511
20	The Prevention of Ventilator-Associated Pneumonia. New England Journal of Medicine, 1999, 340, 627-634.	13.9	504
21	Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, 2005, 49, 1306-1311.	1.4	485
22	The Importance of Fluid Management in Acute Lung Injury Secondary to Septic Shock. Chest, 2009, 136, 102-109.	0.4	436
23	Beforeâ€“after study of a standardized hospital order set for the management of septic shock*. Critical Care Medicine, 2006, 34, 2707-2713.	0.4	424
24	Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA - Journal of the American Medical Association, 2020, 323, 1478.	3.8	419
25	Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia. JAMA - Journal of the American Medical Association, 2008, 300, 805.	3.8	414
26	A Randomized Clinical Trial Comparing an Extended-Use Hygroscopic Condenser Humidifier With Heated-Water Humidification in Mechanically Ventilated Patients. Chest, 1998, 113, 759-767.	0.4	384
27	Antibiotic Resistance in the Intensive Care Unit. Annals of Internal Medicine, 2001, 134, 298.	2.0	382
28	Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control. Clinical Infectious Diseases, 2012, 54, 1739-1746.	2.9	377
29	The Effect of Late-Onset Ventilator-Associated Pneumonia in Determining Patient Mortality. Chest, 1995, 108, 1655-1662.	0.4	376
30	Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Critical Care Medicine, 2004, 32, 1396-1405.	0.4	373
31	Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience. Antimicrobial Agents and Chemotherapy, 2007, 51, 3568-3573.	1.4	367
32	Clinical Characteristics and Treatment Patterns Among Patients With Ventilator-Associated Pneumonia. Chest, 2006, 129, 1210-1218.	0.4	352
33	A Randomized Controlled Trial of an Antibiotic Discontinuation Policy for Clinically Suspected Ventilator-Associated Pneumonia. Chest, 2004, 125, 1791-1799.	0.4	349
34	A Randomized Clinical Trial of Continuous Aspiration of Subglottic Secretions in Cardiac Surgery Patients. Chest, 1999, 116, 1339-1346.	0.4	314
35	The Occurrence of Ventilator-Associated Pneumonia in a Community Hospital. Chest, 2001, 120, 555-561.	0.4	310
36	Probiotic Prophylaxis of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1058-1064.	2.5	308

#	Article	IF	Citations
37	A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clinical Therapeutics, 2007, 29, 1107-1115.	1.1	303
38	Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort. Infection Control and Hospital Epidemiology, 2012, 33, 250-256.	1.0	303
39	Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Medicine, 2004, 30, 388-394.	3.9	301
40	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infectious Diseases, The, 2018, 18, 285-295.	4.6	300
41	Pneumonia Caused by Methicillinâ€ResistantStaphylococcus aureus. Clinical Infectious Diseases, 2008, 46, S378-S385.	2.9	291
42	Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia*. Critical Care Medicine, 2002, 30, 2407-2412.	0.4	288
43	Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. Journal of Parenteral and Enteral Nutrition, 2002, 26, 174-181.	1.3	280
44	Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database*. Critical Care Medicine, 2006, 34, 2588-2595.	0.4	270
45	Risk Factors for Ventilatorâ€Associated Pneumonia: From Epidemiology to Patient Management. Clinical Infectious Diseases, 2004, 38, 1141-1149.	2.9	258
46	A Comparative Analysis of Patients With Early-Onset vs Late-Onset Nosocomial Pneumonia in the ICU Setting. Chest, 2000, 117, 1434-1442.	0.4	256
47	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infectious Diseases, The, 2021, 21, 213-225.	4.6	255
48	Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Critical Care, 2014, 18, 596.	2.5	247
49	Mechanical Ventilator Weaning Protocols Driven by Nonphysician Health-Care Professionals. Chest, 2001, 120, 454S-463S.	0.4	240
50	Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens. Clinical Infectious Diseases, 2011, 52, 31-40.	2.9	239
51	Predictors of 30-Day Mortality and Hospital Costs in Patients With Ventilator-Associated Pneumonia Attributed to Potentially Antibiotic-Resistant Gram-Negative Bacteria. Chest, 2008, 134, 281-287.	0.4	238
52	Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Careâ€“Associated Pneumonia. Chest, 2006, 130, 947-955.	0.4	237
53	The Effect of an Education Program on the Incidence of Central Venous Catheter-Associated Bloodstream Infection in a Medical ICU. Chest, 2004, 126, 1612-1618.	0.4	235
54	Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clinical Therapeutics, 2003, 25, 980-992.	1.1	227

#	Article	IF	Citations
55	Why Do Physicians Not Follow Evidence-Based Guidelines for Preventing Ventilator-Associated Pneumonia?. Chest, 2002, 122, 656-661.	0.4	221
56	Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis. Antimicrobial Agents and Chemotherapy, 2010, 54, 1742-1748.	1.4	221
57	Ceftolozaneâ€“tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infectious Diseases, The, 2019, 19, 1299-1311.	4.6	218
58	Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis. Critical Care Medicine, 2005, 33, 46-53.	0.4	214
59	Broadâ€Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front. Clinical Infectious Diseases, 2008, 47, S3-S13.	2.9	213
60	An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical Care, 2015, 19, 219.	2.5	209
61	An Educational Intervention to Reduce Ventilator-Associated Pneumonia in an Integrated Health System. Chest, 2004, 125, 2224-2231.	0.4	207
62	Red blood cell transfusion and ventilator-associated pneumonia: A potential link?. Critical Care Medicine, 2004, 32, 666-674.	0.4	202
63	The Safety and Diagnostic Accuracy of Minibronchoalveolar Lavage in Patients with Suspected Ventilator-Associated Pneumonia. Annals of Internal Medicine, 1995, 122, 743.	2.0	194
64	Prediction of Infection Due to Antibiotic-Resistant Bacteria by Select Risk Factors for Health Careâ€“Associated Pneumonia. Archives of Internal Medicine, 2008, 168, 2205.	4.3	194
65	Pleuropulmonary Complications of Panton-Valentine Leukocidin-Positive Community-Acquired Methicillin-Resistant Staphylococcus aureus. Chest, 2005, 128, 2732-2738.	0.4	181
66	Silver-Coated Endotracheal Tubes Associated With Reduced Bacterial Burden in the Lungs of Mechanically Ventilated Dogs. Chest, 2002, 121, 863-870.	0.4	173
67	A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Critical Care, 2012, 16, R218.	2.5	173
68	Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay*. Critical Care Medicine, 2011, 39, 46-51.	0.4	162
69	The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs, 2021, 81, 2117-2131.	4.9	161
70	Treatment-related risk factors for hospital mortality in Candida bloodstream infections*. Critical Care Medicine, 2008, 36, 2967-2972.	0.4	158
71	Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa*. Critical Care Medicine, 2014, 42, 2178-2187.	0.4	157
72	Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Medicine, 2019, 45, 172-189.	3.9	155

#	Article	IF	Citations
73	Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Critical Care Medicine, 2000, 28, 3456-3464.	0.4	153
74	Hospital Mortality for Patients With Bacteremia Due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest, 2004, 125, 607-616.	0.4	153
75	Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections. Clinical Infectious Diseases, 2007, 45, S191-S195.	2.9	153
76	Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia*. Critical Care Medicine, 2003, 31, 2693-2696.	0.4	152
77	Mechanical Ventilation with or without 7-Day Circuit Changes. Annals of Internal Medicine, 1995, 123, 168.	2.0	151
78	Improving Family Communications at the End of Life: Implications for Length of Stay in the Intensive Care Unit and Resource Use. American Journal of Critical Care, 2003, 12, 317-324.	0.8	150
79	Validation of a Clinical Score for Assessing the Risk of Resistant Pathogens in Patients With Pneumonia Presenting to the Emergency Department. Clinical Infectious Diseases, 2012, 54, 193-198.	2.9	148
80	Implementation of a real-time computerized sepsis alert in nonintensive care unit patients*. Critical Care Medicine, 2011, 39, 469-473.	0.4	145
81	Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study*. Critical Care Medicine, 2006, 34, 2766-2772.	0.4	144
82	Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment*. Critical Care Medicine, 2006, 34, 2069-2074.	0.4	136
83	A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia. Chest, 2017, 151, 1239-1246.	0.4	136
84	Antimicrobial Therapy Escalation and Hospital Mortality Among Patients With Health-Care-Associated Pneumonia. Chest, 2008, 134, 963-968.	0.4	134
85	Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Critical Care Medicine, 2006, 34, 700-706.	0.4	130
86	Strategies to prevent antimicrobial resistance in the intensive care unit. Critical Care Medicine, 2005, 33, 1845-1853.	0.4	129
87	Short- vs Long-Duration Antibiotic Regimens for Ventilator-Associated Pneumonia. Chest, 2013, 144, 1759-1767.	0.4	127
88	Appropriate Empirical Antibacterial Therapy for Nosocomial Infections. Drugs, 2003, 63, 2157-2168.	4.9	123
89	Secular Trends in Candidemia-Related Hospitalization in the United States, 2000â€“2005. Infection Control and Hospital Epidemiology, 2008, 29, 978-980.	1.0	123
90	Fluid balance and cardiac function in septic shock as predictors of hospital mortality. Critical Care, 2013, 17, R246.	2.5	123

#	Article	IF	Citations
91	Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Critical Care, 2006, 10, R97.	2.5	120
92	Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Critical Care Medicine, 2007, 35, 1077-1083.	0.4	118
93	Duration of Exposure to Antipseudomonal Î²â€Lactam Antibiotics in the Critically Ill and Development of New Resistance. Pharmacotherapy, 2019, 39, 261-270.	1.2	116
94	Transfusion Practice and Blood Stream Infections in Critically Ill Patients. Chest, 2005, 127, 1722-1728.	0.4	115
95	A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria*. Critical Care Medicine, 2012, 40, 281-284.	0.4	115
96	Health careâ€“associated pneumonia: identification and initial management in the ED. American Journal of Emergency Medicine, 2008, 26, 1-11.	0.7	112
97	Health Careâ€“Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomesâ€”Proceedings of the HCAP Summit. Clinical Infectious Diseases, 2008, 46, S296-S334.	2.9	111
98	A Randomized Double-Blind Trial of Iseganan in Prevention of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 91-97.	2.5	110
99	Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results. Chest, 2005, 128, 2706-2713.	0.4	108
100	A Prospective Evaluation of Ventilator-Associated Conditions and Infection-Related Ventilator-Associated Conditions. Chest, 2015, 147, 68-81.	0.4	106
101	The Use of Inhaled Prostaglandins in Patients With ARDS. Chest, 2015, 147, 1510-1522.	0.4	106
102	Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis*. Critical Care Medicine, 2009, 37, 819-824.	0.4	105
103	Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Critical Care Medicine, 2004, 32, 2450-2456.	0.4	104
104	Probiotics for preventing ventilator-associated pneumonia. The Cochrane Library, 2014, , CD009066.	1.5	104
105	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	3.9	103
106	Selective Digestive Decontamination Should Not Be Routinely Employed*. Chest, 2003, 123, 464S-468S.	0.4	101
107	Economic Burden of Ventilator-Associated Pneumonia Based on Total Resource Utilization. Infection Control and Hospital Epidemiology, 2010, 31, 509-515.	1.0	100
108	Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Medicine, 2019, 45, 159-171.	3.9	100

#	Article	IF	Citations
109	A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes. Chest, 2016, 150, 1008-1014.	0.4	99
110	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Medicine, 2020, 46, 245-265.	3.9	97
111	Re-estimating annual deaths due to multidrug-resistant organism infections. Infection Control and Hospital Epidemiology, 2019, 40, 112-113.	1.0	91
112	Staphylococcus aureusNasal Colonization and Subsequent Infection in Intensive Care Unit Patients: Does Methicillin Resistance Matter?. Infection Control and Hospital Epidemiology, 2010, 31, 584-591.	1.0	90
113	Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: A multicenter cohort study. Journal of Infection, 2011, 62, 130-135.	1.7	90
114	Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality*. Critical Care Medicine, 2018, 46, 736-742.	0.4	90
115	Early Palliative Care Consultation in the Medical ICU: A Cluster Randomized Crossover Trial. Critical Care Medicine, 2019, 47, 1707-1715.	0.4	90
116	Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infectionsâ€"Proceedings and Data From the Gram-Negative Resistance Summit. Clinical Infectious Diseases, 2011, 53, S33-S55.	2.9	88
117	Using the Number Needed to Treat to Assess Appropriate Antimicrobial Therapy as a Determinant of Outcome in Severe Sepsis and Septic Shock*. Critical Care Medicine, 2014, 42, 2342-2349.	0.4	88
118	A Comparison of Culture-Positive and Culture-Negative Health-Care-Associated Pneumonia. Chest, 2010, 137, 1130-1137.	0.4	87
119	Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis*. Critical Care Medicine, 2011, 39, 1859-1865.	0.4	87
120	Implementing quality improvements in the intensive care unit: Ventilator bundle as an example. Critical Care Medicine, 2009, 37, 305-309.	0.4	85
121	Ventilator-Associated Tracheobronchitis in a Mixed Surgical and Medical ICU Population. Chest, 2011, 139, 513-518.	0.4	84
122	Use of Adjunctive Aerosolized Antimicrobial Therapy in the Treatment ofPseudomonas aeruginosaandAcinetobacter baumanniiVentilator-Associated Pneumonia. Respiratory Care, 2012, 57, 1226-1233.	0.8	84
123	Hospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia. Pharmacotherapy, 2010, 30, 361-368.	1.2	82
124	Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. Journal of Hospital Medicine, 2016, 11, 21-26.	0.7	82
125	Nosocomial Infection. Critical Care Medicine, 2021, 49, 169-187.	0.4	82
126	What is ventilator-associated pneumonia and why is it important?. Respiratory Care, 2005, 50, 714-21; discussion 721-4.	0.8	82

#	Article	IF	Citations
127	Association between augmented renal clearance and clinical outcomes in patients receiving Î²-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. International Journal of Antimicrobial Agents, 2017, 49, 624-630.	1.1	80
128	Bacterial and fungal superinfections in critically ill patients with COVID-19. Intensive Care Medicine, 2020, 46, 2071-2074.	3.9	79
129	Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit?. Clinical Infectious Diseases, 2006, 43, S82-S88.	2.9	78
130	A randomized trial of realâ€time automated clinical deterioration alerts sent to a rapid response team. Journal of Hospital Medicine, 2014, 9, 424-429.	0.7	78
131	Diagnostic Implications of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in BAL Fluid of Patients With Pulmonary Infiltrates in the ICU. Chest, 2009, 135, 641-647.	0.4	73
132	The number of discharge medications predicts thirty-day hospital readmission: a cohort study. BMC Health Services Research, 2015, 15, 282.	0.9	73
133	Inappropriate therapy for methicillin-resistant Staphylococcus aureus: Resource utilization and cost implications*. Critical Care Medicine, 2008, 36, 2335-2340.	0.4	72
134	Pulmonary infections complicating ARDS. Intensive Care Medicine, 2020, 46, 2168-2183.	3.9	69
135	A Cost-Benefit Analysis of Gown Use in Controlling Vancomycin-ResistantEnterococcusTransmission Is It Worth the Price?. Infection Control and Hospital Epidemiology, 2004, 25, 418-424.	1.0	68
136	The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. Critical Care Medicine, 2012, 40, 2016-2021.	0.4	68
137	Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections. Open Forum Infectious Diseases, 2018, 5, ofy026.	0.4	68
138	Ventilator-Associated Pneumonia in a Multi-Hospital System Differences in Microbiology by Location. Infection Control and Hospital Epidemiology, 2003, 24, 853-858.	1.0	67
139	Cost-Effectiveness Analysis of a Silver-Coated Endotracheal Tube to Reduce the Incidence of Ventilator-Associated Pneumonia. Infection Control and Hospital Epidemiology, 2009, 30, 759-763.	1.0	67
140	A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infectious Diseases, 2013, 13, 268.	1.3	67
141	Use of Hypochlorite Solution to Decrease Rates of Clostridium difficile-Associated Diarrhea. Infection Control and Hospital Epidemiology, 2007, 28, 205-207.	1.0	64
142	Targeted Fluid Minimization Following Initial Resuscitation in Septic Shock. Chest, 2015, 148, 1462-1469.	0.4	64
143	Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen?. Current Opinion in Infectious Diseases, 2006, 19, 161-168.	1.3	63
144	Recognition and prevention of nosocomial pneumonia in the intensive care unit and infection control in mechanical ventilation. Critical Care Medicine, 2010, 38, S352-S362.	0.4	62

#	Article	IF	Citations
145	Clostridium difficile in the ICU. Chest, 2011, 140, 1643-1653.	0.4	62
146	Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment. Critical Care Medicine, 2010, 38, 1991-1995.	0.4	61
147	Association Between a Silver-Coated Endotracheal Tube and Reduced Mortality in Patients With Ventilator-Associated Pneumonia. Chest, 2010, 137, 1015-1021.	0.4	61
148	Diagnosis of Ventilator-Associated Pneumonia. New England Journal of Medicine, 2006, 355, 2691-2693.	13.9	60
149	The Alphabet Soup of Pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 003-009.	0.8	60
150	Using wearable technology to predict health outcomes: a literature review. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1221-1227.	2.2	60
151	Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy*. Critical Care Medicine, 2015, 43, 1580-1586.	0.4	59
152	Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation*. Critical Care Medicine, 2010, 38, 1135-1140.	0.4	58
153	Initial antimicrobial management of sepsis. Critical Care, 2021, 25, 307.	2.5	58
154	Health Careâ€“Associated Infection (HAI): A Critical Appraisal of the Emerging Threatâ€”Proceedings of the HAI Summit. Clinical Infectious Diseases, 2008, 47, S55-S99.	2.9	56
155	Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review. Intensive Care Medicine, 2016, 42, 1899-1911.	3.9	56
156	Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. International Journal of Infectious Diseases, 2011, 15, e545-e550.	1.5	55
157	Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram-negative bacteremia. Journal of Hospital Medicine, 2011, 6, 405-410.	0.7	55
158	Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary. Clinical Infectious Diseases, 2013, 57, 1742-1746.	2.9	55
159	Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival. Antimicrobial Agents and Chemotherapy, 2014, 58, 2030-2037.	1.4	55
160	Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	55
161	The Importance of Early Treatment With Doxycycline in Human Ehrlichiosis. Medicine (United States), 2008, 87, 53-60.	0.4	54
162	Timing of antibiotic therapy in the ICU. Critical Care, 2021, 25, 360.	2.5	54

#	Article	IF	Citations
163	Probiotics for Preventing and Treating Nosocomial Infections. Chest, 2007, 132, 286-294.	0.4	53
164	Viruses are prevalent in non-ventilated hospital-acquired pneumonia. Respiratory Medicine, 2017, 122, 76-80.	1.3	53
165	Epidemiology and Outcomes of Hospitalizations with Complicated Skin and Skin-Structure Infections: Implications of Healthcare-Associated Infection Risk Factors. Infection Control and Hospital Epidemiology, 2009, 30, 1203-1210.	1.0	49
166	Readmission Following Hospitalization for Pneumonia: The Impact of Pneumonia Type and Its Implication for Hospitals. Clinical Infectious Diseases, 2013, 57, 362-367.	2.9	48
167	Epidemiology and Outcomes of Clostridium difficile -Associated Disease Among Patients on Prolonged Acute Mechanical Ventilation. Chest, 2009, 136, 752-758.	0.4	45
168	Aerosolized antibiotics. Current Opinion in Infectious Diseases, 2013, 26, 538-544.	1.3	45
169	Prolonged Infusion Antibiotics for Suspected Gram-Negative Infections in the ICU: A Before-After Study. Annals of Pharmacotherapy, 2013, 47, 170-180.	0.9	44
170	Hospitalizations with healthcareâ€associated complicated skin and skin structure infections: Impact of inappropriate empiric therapy on outcomes. Journal of Hospital Medicine, 2010, 5, 535-540.	0.7	41
171	The Burden of Viruses in Pneumonia Associated With Acute Respiratory Failure. Chest, 2018, 154, 84-90.	0.4	41
172	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. ERJ Open Research, 2018, 4, 00028-2018.	1.1	41
173	Predictors of Hospital Mortality for Patients with Severe Sepsis Treated with Drotrecogin alfa (activated). Pharmacotherapy, 2005, 25, 26-34.	1.2	39
174	SMART Approaches for Reducing Nosocomial Infections in the ICU. Chest, 2008, 134, 447-456.	0.4	39
175	Health Care-Associated Pneumonia (HCAP). Medicine (United States), 2011, 90, 390-395.	0.4	39
176	The Modified APACHE II Score Outperforms Curb65 Pneumonia Severity Score as a Predictor of 30-Day Mortality in Patients With Methicillin-Resistant Staphylococcus aureus Pneumonia. Chest, 2008, 133, 363-369.	0.4	38
177	Antibiotic Stewardship in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 215-227.	0.8	38
178	Predictors of In-Hospital Mortality for Bloodstream Infections Caused byEnterobacterSpecies orCitrobacter freundii. Pharmacotherapy, 2007, 27, 191-199.	1.2	37
179	Antimicrobial stewardship programs: mandatory for all ICUs. Critical Care, 2012, 16, 179.	2.5	37
180	Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients With Bloodstream Infection Due to Gram-Negative Bacteria. Clinical Infectious Diseases, 2017, 65, 1607-1614.	2.9	37

#	Article	IF	Citations
181	Candidemia on presentation to the hospital: development and validation of a risk score. Critical Care, 2009, 13, R156.	2.5	36
182	Treatment of severe skin and soft tissue infections: a review. Current Opinion in Infectious Diseases, 2018, 31, 113-119.	1.3	36
183	Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia. Chest, 2019, 155, 53-59.	0.4	36
184	Pseudomonas aeruginosaNosocomial Pneumonia: Impact of Pneumonia Classification. Infection Control and Hospital Epidemiology, 2015, 36, 1190-1197.	1.0	34
185	Gram-Negative Bacterial Resistance: Evolving Patterns and Treatment Paradigms. Clinical Infectious Diseases, 2005, 40, S85-S88.	2.9	33
186	Providing appropriate antimicrobial therapy in the intensive care unit: Surveillance vs. de-escalation*. Critical Care Medicine, 2006, 34, 903-905.	0.4	33
187	An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infectious Diseases, 2012, 12, 56.	1.3	33
188	Frequent Versus Infrequent Monitoring of Endotracheal Tube Cuff Pressures. Respiratory Care, 2018, 63, 495-501.	0.8	33
189	Prevention of hospital-acquired pneumonia. Current Opinion in Critical Care, 2018, 24, 370-378.	1.6	33
190	Spot the difference: comparing results of analyses from real patient data and synthetic derivatives. JAMIA Open, 2021, 3, 557-566.	1.0	33
191	Treatment of gram - positive infections in critically ill patients. BMC Infectious Diseases, 2014, 14, 92.	1.3	32
192	Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship. Critical Care, 2015, 19, 404.	2.5	32
193	New antibiotics for community-acquired pneumonia. Current Opinion in Infectious Diseases, 2019, 32, 169-175.	1.3	32
194	Understanding toxic shock syndrome. Intensive Care Medicine, 2015, 41, 1707-1710.	3.9	31
195	Predicting Bacteremia among Patients Hospitalized for Skin and Skin-Structure Infections: Derivation and Validation of a Risk Score. Infection Control and Hospital Epidemiology, 2010, 31, 828-837.	1.0	30
196	Diagnostic Utility of Plasma Procalcitonin for Nosocomial Pneumonia in the Intensive Care Unit Setting. Respiratory Care, 2011, 56, 412-419.	0.8	30
197	Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Intensive Care Medicine, 2003, 29, 147-149.	3.9	29
198	Prevention of ventilator-associated pneumonia or ventilator-associated complications. Critical Care Medicine, 2012, 40, 271-277.	0.4	29

#	Article	IF	Citations
199	Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection. Medicine (United States), 2018, 97, e12782.	0.4	29
200	Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department. BMC Infectious Diseases, 2014, 14, 61.	1.3	28
201	Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia. Pharmacotherapy, 2006, 26, 204-213.	1.2	27
202	Pneumonia Pathogen Characterization Is an Independent Determinant of Hospital Readmission. Chest, 2015, 148, 103-111.	0.4	27
203	Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy. Clinical Infectious Diseases, 2018, 67, 1455-1462.	2.9	27
204	Monocyte Function and Clinical Outcomes in Febrile and Afebrile Patients With Severe Sepsis. Shock, 2018, 50, 381-387.	1.0	27
205	Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respiratory Care, 2004, 49, 1530-41.	0.8	27
206	Rational Use of Antibiotics in the ICU. JAMA - Journal of the American Medical Association, 2014, 312, 1403.	3.8	26
207	Update on ventilator-associated pneumonia. Current Opinion in Critical Care, 2015, 21, 430-438.	1.6	26
208	Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock. Journal of Critical Care, 2015, 30, 715-720.	1.0	26
209	Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 253-263.	0.8	26
210	Medical Data Mining for Early Deterioration Warning in General Hospital Wards. , 2011, , .		25
211	Quinolones for Treatment of Nosocomial Pneumonia: A Meta-Analysis. Clinical Infectious Diseases, 2005, 40, S115-S122.	2.9	24
212	Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients. Infection Control and Hospital Epidemiology, 2015, 36, 1451-1454.	1.0	24
213	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clinical Infectious Diseases, 2019, 69, 1912-1918.	2.9	24
214	Culture-negative sepsis. Current Opinion in Critical Care, 2020, 26, 473-477.	1.6	24
215	Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit. Critical Care, 2005, 9, 459.	2.5	23
216	Predictors of Outcome in 216 Subjects With ARDS Treated With Inhaled Epoprostenol. Respiratory Care, 2014, 59, 1178-1185.	0.8	23

#	Article	IF	Citations
217	Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study. Critical Care, 2017, 21, 180.	2.5	23
218	Prevention of Nosocomial Pneumonia in the Intensive Care Unit: Beyond the Use of Bundles. Surgical Infections, 2011, 12, 211-220.	0.7	22
219	Ventilator-associated Complications, Including Infection-related Complications. Critical Care Clinics, 2013, 29, 33-50.	1.0	22
220	A Respiratory Therapist Disease Management Program for Subjects Hospitalized With COPD. Respiratory Care, 2017, 62, 1-9.	0.8	22
221	Review of Recent Clinical Trials of Hospitalâ€Acquired Pneumonia and Ventilatorâ€Associated Pneumonia: A Perspective from Academia. Clinical Infectious Diseases, 2010, 51, S29-S35.	2.9	21
222	Reducing the Burden of Acute Respiratory Distress Syndrome. Shock, 2014, 41, 378-387.	1.0	21
223	Identifying Critically Ill Patients at Risk for Inappropriate Antibiotic Therapy. Critical Care Medicine, 2014, 42, 1832-1838.	0.4	21
224	Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. Critical Care, 2021, 25, 290.	2.5	21
225	Addition of Vasopressin to Norepinephrine as Independent Predictor of Mortality in Patients with Refractory Septic Shock: An Observational Study. Surgical Infections, 2007, 8, 189-200.	0.7	20
226	Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	20
227	Moving Towards Real-Time Antimicrobial Management of Ventilator-Associated Pneumonia. Clinical Infectious Diseases, 2007, 44, 388-390.	2.9	19
228	PROPHETIC. Chest, 2020, 158, 2370-2380.	0.4	19
229	Cluster analysis to define distinct clinical phenotypes among septic patients with bloodstream infections. Medicine (United States), 2019, 98, e15276.	0.4	18
230	Clinical effectiveness of a sedation protocol minimizing benzodiazepine infusions and favoring early dexmedetomidine: a before-after study. Critical Care, 2015, 19, 136.	2.5	17
231	Clinical Effect of Expedited Pathogen Identification and Susceptibility Testing for Gram-Negative Bacteremia and Candidemia by Use of the Accelerate PhenoTM System. journal of applied laboratory medicine, The, 2019, 3, 569-579.	0.6	17
232	New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. Antimicrobial Agents and Chemotherapy, 2021, 65, e0231820.	1.4	17
233	Management of Severe Sepsis: Integration of Multiple Pharmacologic Interventions. Pharmacotherapy, 2003, 23, 1486-1496.	1.2	16
234	A 50-Year-Old Woman With Abdominal Pain and Respiratory Failure 3 Months After Kidney Transplantation. Chest, 2008, 134, 442-446.	0.4	16

#	Article	IF	Citations
235	Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 5546-5553.	1.4	16
236	Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection. Infection Control and Hospital Epidemiology, 2018, 39, 12-19.	1.0	16
237	Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	16
238	Evaluating the Value of the Respiratory Therapist: Where Is the Evidence? Focus on the Barnes-Jewish Hospital Experience. Respiratory Care, 2017, 62, 1602-1610.	0.8	16
239	Bacteremia Increases the Risk of Death among Patients with Soft-Tissue Infections. Surgical Infections, 2010, 11, 169-176.	0.7	15
240	What can be expected from antimicrobial de-escalation in the critically ill?. Intensive Care Medicine, 2014, 40, 92-95.	3.9	15
241	Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study. Critical Care, 2015, 19, 312.	2.5	15
242	Surveillance versus clinical adjudication: Differences persist with new ventilator-associated event definition. American Journal of Infection Control, 2015, 43, 589-591.	1.1	15
243	Is Zero Ventilator-Associated Pneumonia Achievable?. Clinics in Chest Medicine, 2018, 39, 809-822.	0.8	15
244	A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	15
245	Comparison of Sepsis Definitions as Automated Criteria. Critical Care Medicine, 2021, 49, e433-e443.	0.4	15
246	Time To Get Serious About Infection Prevention in the ICU. Chest, 2006, 130, 1293-1296.	0.4	14
247	Risk factors for 30â€day readmission among patients with cultureâ€positive severe sepsis and septic shock: A retrospective cohort study. Journal of Hospital Medicine, 2015, 10, 678-685.	0.7	14
248	Characteristics of U.S. Acute Care Hospitals That Have Implemented Telemedicine Critical Care. , 2021, 3, e0468.		14
249	Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Critical Care, 2021, 25, 354.	2.5	14
250	Î²-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value. , 2022, 4, e0726.		14
251	Microbiological Diagnosis of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1182-1184.	2.5	13
252	Controversies and advances in the management of ventilator associated pneumonia. Expert Review of Respiratory Medicine, 2017, 11, 875-884.	1.0	13

#	Article	IF	Citations
253	Azithromycin and survival inStreptococcus pneumoniaepneumonia: a retrospective study. BMJ Open, 2013, 3, e002898.	0.8	12
254	Novel Approaches to Hasten Detection of Pathogens and Antimicrobial Resistance in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 454-464.	0.8	12
255	VAT vs VAP. Chest, 2009, 135, 252-255.	0.4	11
256	Risk Factors for Mixed Complicated Skin and Skin Structure Infections To Help Tailor Appropriate Empiric Therapy. Surgical Infections, 2012, 13, 377-382.	0.7	11
257	Determinants of Hospital Mortality Among Patients with Sepsis or Septic Shock Receiving Appropriate Antibiotic Treatment. Current Infectious Disease Reports, 2013, 15, 400-406.	1.3	11
258	Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?. American Journal of Infection Control, 2018, 46, 1092-1096.	1.1	11
259	A Pragmatic Machine Learning Model To Predict Carbapenem Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0006321.	1.4	11
260	The carbon footprint of treating patients with septic shock in the intensive care unit. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2018, 20, 304-312.	0.0	11
261	Prevention of hospital infection. Microbes and Infection, 2005, 7, 268-274.	1.0	10
262	Introduction: Update on the Appropriate Use of Meropenem for the Treatment of Serious Bacterial Infections. Clinical Infectious Diseases, 2008, 47, S1-S2.	2.9	10
263	Oral Decontamination to Prevent Ventilator-Associated Pneumonia. Chest, 2009, 135, 1116-1118.	0.4	10
264	Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators. Critical Care, 2010, 14, R84.	2.5	10
265	Conservative fluid therapy in septic shock: an example of targeted therapeutic minimization. Critical Care, 2014, 18, 481.	2.5	10
266	Effects of Empiric Antifungal Therapy for Septic Shock on Time to Appropriate Therapy for Candida Infection: A Pilot Study. Clinical Therapeutics, 2014, 36, 1226-1232.	1.1	10
267	Ventilator-associated Pneumonia Prevention. Is It Worth It?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 5-7.	2.5	10
268	qSOFA score: Predictive validity in Enterobacteriaceae bloodstream infections. Journal of Critical Care, 2018, 43, 143-147.	1.0	10
269	Pathogen-Negative Sepsisâ€"An Opportunity for Antimicrobial Stewardship. Open Forum Infectious Diseases, 2019, 6, ofz397.	0.4	10
270	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. Lancet Infectious Diseases, The, 2022, 22, e74-e87.	4.6	10

#	Article	IF	Citations
271	New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2009, 11, 282-6.	0.0	10
272	Will procalcitonin reduce antibiotic use in intensive care?. Lancet, The, 2010, 375, 435-436.	6.3	9
273	Ventilator-Associated Pneumonia. Chest, 2015, 147, 1448-1450.	0.4	9
274	COUNTERPOINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? No. Chest, 2017, 151, 740-743.	0.4	9
275	A Prospective One-Year Microbiologic Survey of Combined Pneumonia and Respiratory Failure. Surgical Infections, 2017, 18, 827-833.	0.7	9
276	Augmented renal clearance is not a risk factor for mortality in Enterobacteriaceae bloodstream infections treated with appropriate empiric antimicrobials. PLoS ONE, 2017, 12, e0180247.	1.1	9
277	Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	9
278	Racial Disparities in Readmissions Following Initial Hospitalization for Sepsis. Critical Care Medicine, 2021, 49, e258-e268.	0.4	9
279	Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab508.	0.4	9
280	Healthcare-Associated Pneumonia: Approach to Management. Clinics in Chest Medicine, 2011, 32, 507-515.	0.8	8
281	In 2035, will all bacteria be multiresistant? Yes. Intensive Care Medicine, 2016, 42, 2014-2016.	3.9	8
282	Editorial Commentary: Antimicrobial De-escalation: What's in a Name?. Clinical Infectious Diseases, 2016, 62, 1018-1020.	2.9	8
283	â€œDoes this patient haveâ€¦â€•â€œIs this patient at risk for infection with multidrug resistant bacteria?â€• Intensive Care Medicine, 2017, 43, 436-439.	3.9	8
284	Optimizing Therapy for MRSA Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 615-623.	0.8	7
285	Severe hospital-acquired pneumonia: A review for clinicians. Current Infectious Disease Reports, 2009, 11, 349-356.	1.3	7
286	Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Colonization Predicts Intensive Care Unit-Acquired MRSA Infections: True Or False?. Surgical Infections, 2010, 11, 497-499.	0.7	7
287	To which extent can we decrease antibiotic duration in critically ill patients?. Expert Review of Clinical Pharmacology, 2017, 10, 1215-1223.	1.3	7
288	CAP, HCAP, HAP,ÂVAP. Chest, 2017, 152, 909-910.	0.4	7

#	Article	IF	Citations
289	Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia. Clinical Therapeutics, 2019, 41, 2540-2548.	1.1	7
290	Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill. Infection Control and Hospital Epidemiology, 2020, 41, 484-485.	1.0	7
291	Monoclonal antibodies as antibacterial therapies: thinking outside of the box. Lancet Infectious Diseases, The, 2021, 21, 1201-1202.	4.6	7
292	Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. Journal of Antimicrobial Chemotherapy, 2022, 77, 1166-1177.	1.3	7
293	Patients Hospitalized With Pneumonia: Determining the Need for Broad-Spectrum Antibiotic Therapy. Clinical Infectious Diseases, 2012, 54, 479-482.	2.9	6
294	Management of Infections with Drug-Resistant Organisms in Critical Care. Clinics in Chest Medicine, 2015, 36, 531-541.	0.8	6
295	ICD-9-CM Coding for Multidrug Resistant Infection Correlates Poorly With Microbiologically Confirmed Multidrug Resistant Infection. Infection Control and Hospital Epidemiology, 2017, 38, 1381-1383.	1.0	6
296	Pneumococcal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistance. Respiratory Medicine, 2021, 177, 106307.	1.3	6
297	Early Deterioration Warning for Hospitalized Patients by Mining Clinical Data. International Journal of Knowledge Discovery in Bioinformatics, 2011, 2, 1-20.	0.8	6
298	The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance. Surgical Infections, 2006, 7, 85-99.	0.7	5
299	Clinical Practice Improvement Initiatives. Chest, 2009, 136, 335-338.	0.4	5
300	The Impact of Nighttime Intensivists on Medical Intensive Care Unit Infection-Related Indicators. Infection Control and Hospital Epidemiology, 2016, 37, 352-354.	1.0	5
301	Prevention of Staphylococcus aureus Ventilator-Associated Pneumonia: Conventional Antibiotics Wonâ€™t Cut It. Clinical Infectious Diseases, 2017, 64, 1089-1091.	2.9	5
302	POINT: Does Persistent or Worsening ARDS Refractory to Optimized Ventilation and Proning Deserve a Trial of Prostacyclin? Yes. Chest, 2019, 155, 662-665.	0.4	5
303	Postoperative Pneumonia Prevention inÂPulmonary Resections: A Feasibility Pilot Study. Annals of Thoracic Surgery, 2019, 107, 262-270.	0.7	5
304	Bloodstream Infections and Delayed Antibiotic Coverage Are Associated With Negative Hospital Outcomes in Hematopoietic Stem Cell Transplant Recipients. Chest, 2020, 158, 1385-1396.	0.4	5
305	Race Does Not Impact Sepsis Outcomes When Considering Socioeconomic Factors in Multilevel Modeling. Critical Care Medicine, 2022, 50, 410-417.	0.4	5
306	Mortality Prediction in ICUs Using A Novel Time-Slicing Cox Regression Method. AMIA ... Annual Symposium proceedings, 2015, 2015, 1289-95.	0.2	5

#	Article	IF	Citations
307	Prevention of Pneumonia in the Hospital Setting. Clinics in Chest Medicine, 2005, 26, 135-142.	0.8	4
308	Health-Care-Associated Pneumonia. Chest, 2009, 135, 594-596.	0.4	4
309	Health Care-Associated Pneumonia. Hospital Practice (1995), 2010, 38, 63-74.	0.5	4
310	Probiotics for Ventilator-Associated Pneumonia. Chest, 2013, 143, 590-592.	0.4	4
311	Thirty-day hospital readmissions among mechanically ventilated emergency department patients. Emergency Medicine Journal, 2018, 35, 252-256.	0.4	4
312	The most recent concepts for the management of bacterial and fungal infections in ICU. Intensive Care Medicine, 2018, 44, 2000-2003.	3.9	4
313	Antibiotic Thresholds for Sepsis and Septic Shock. Clinical Infectious Diseases, 2019, 69, 938-940.	2.9	4
314	Impact of Baseline Characteristics on Future Episodes of Bloodstream Infections: Multistate Model in Septic Patients With Bloodstream Infections. Clinical Infectious Diseases, 2020, 71, 3103-3109.	2.9	4
315	Characteristics and outcomes among a hospitalized patient cohort with Streptococcus pneumoniae infection. Medicine (United States), 2020, 99, e20145.	0.4	4
316	Soluble Triggering Receptor Expressed on Myeloid Cells 1 and the Diagnosis of Ventilator-Associated Pneumonia: Response. Chest, 2009, 136, 320.	0.4	3
317	Increased Mortality in Patients Without Ventilator-Associated Pneumonia: Response. Chest, 2010, 138, 1275.	0.4	3
318	Recognition of Nosocomial Pneumonia in the Intensive Care Unit: Still a Confusing Issue. Respiratory Care, 2011, 56, 1209-1212.	0.8	3
319	Ventilator-Associated Tracheobronchitis and Ventilator-Associated Pneumonia. Chest, 2013, 144, 3-5.	0.4	3
320	Candidemia and non-candidemia related septic shock: are there differences between them?. Intensive Care Medicine, 2014, 40, 1046-1048.	3.9	3
321	Ventilator-Associated Pneumonia Prevention. Chest, 2014, 146, 873-874.	0.4	3
322	Real-time automated clinical deterioration alerts predict thirty-day hospital readmission. Journal of Hospital Medicine, 2016, 11, 768-772.	0.7	3
323	A targeted educational intervention to reduce ventilator-associated complications. American Journal of Infection Control, 2016, 44, 1406-1407.	1.1	3
324	Use of a Shared Canister Protocol for the Delivery of Metered-Dose Inhalers in Mechanically Ventilated Subjects. Respiratory Care, 2016, 61, 1285-1292.	0.8	3

#	Article	IF	Citations
325	Differences in mortality between infections due to extended-spectrum-beta-lactamaseâ€“producing Klebsiella pneumoniae and Escherichia coli. Infection Control and Hospital Epidemiology, 2018, 39, 1138-1139.	1.0	3
326	Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill. Clinical Infectious Diseases, 2020, 70, 1520-1521.	2.9	3
327	Reduction in antimicrobial use among medical intensive care unit patients during a cluster randomized crossover trial of palliative care consultation. Infection Control and Hospital Epidemiology, 2019, 40, 491-492.	1.0	3
328	Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial. Infectious Diseases and Therapy, 2020, 9, 953-966.	1.8	3
329	Prospective Nasal Screening for Methicillin-Resistant Staphylococcus aureus in Critically Ill Patients With Suspected Pneumonia. Open Forum Infectious Diseases, 2022, 9, ofab578.	0.4	3
330	Classical and Molecular Techniques to Diagnose HAP/VAP. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 219-228.	0.8	3
331	Impact of Stress Ulcer Prophylaxis Discontinuation Guidance in Mechanically Ventilated, Critically Ill Patients: A Pre-Post Cohort Study. Hospital Pharmacy, 2022, 57, 510-517.	0.4	3
332	The importance of antimicrobial resistance in hospital-acquired and ventilator-associated pneumonia. Current Anaesthesia and Critical Care, 2005, 16, 209-219.	0.3	2
333	Bugging the Bugs: Novel Approaches in the Strategic Management of Resistant Staphylococcus aureus Infections. Clinical Infectious Diseases, 2007, 45, S163-S164.	2.9	2
334	Institutional Perspective on the Impact of Positive Blood Cultures on the Economic and Clinical Outcomes of Patients With Complicated Skin and Skin Structure Infections: Focus on Gram-Positive Infections. Clinical Therapeutics, 2011, 33, 1759-1768.e1.	1.1	2
335	1233A Comparison of National Healthcare Safety Network (NHSN) Ventilator Associated Pneumonia (VAP) and Ventilator Associated Event (VAE) Definitions. Open Forum Infectious Diseases, 2014, 1, S45-S45.	0.4	2
336	Principles of antimicrobial stewardship for bacterial and fungal infections in ICU. Intensive Care Medicine, 2017, 43, 1894-1897.	3.9	2
337	Limitations of Registration Trials for Nosocomial Pneumonia. Clinical Infectious Diseases, 2020, 73, e4549-e4551.	2.9	2
338	Next Steps in Pneumonia Severity Scores. Clinical Infectious Diseases, 2021, 72, 950-952.	2.9	2
339	Preventive Strategies in VAP: Focus on Silver-Coated Endotracheal Tubes. , 2013, , 531-555.		2
340	Preface. Infectious Disease Clinics of North America, 2009, 23, xiii-xiv.	1.9	1
341	The Resuscitation Package in Sepsis. Current Infectious Disease Reports, 2010, 12, 368-373.	1.3	1
342	Ten old antibiotics that will never disappear. Intensive Care Medicine, 2015, 41, 1950-1953.	3.9	1

#	Article	IF	Citations
343	If antibiotics did not exist. Intensive Care Medicine, 2015, 41, 525-527.	3.9	1
344	Rebuttal From Dr Kollef. Chest, 2017, 151, 744-745.	0.4	1
345	Moving the Practice of Respiratory Therapy Forward. Respiratory Care, 2019, 64, 1014-1016.	0.8	1
346	A PRAGMATIC MACHINE LEARNING MODEL TO PREDICT CARBAPENEM RESISTANCE. Chest, 2020, 158, A706.	0.4	1
347	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	1
348	Hospital-Acquired Pneumonia. , 2012, , 137-145.		1
349	Short- Versus Standard-Course Nonmacrolide Antibiotic Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective, Observational Cohort Study. Clinical Therapeutics, 2021, , .	1.1	1
350	Life-Threatening Infections: Pulmonary and Systemic Infections. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 001-002.	0.8	1
351	How to use new antibiotics in the therapy of ventilator-associated pneumonia. Current Opinion in Infectious Diseases, 2022, 35, 140-148.	1.3	1
352	Mechanical Ventilation Practices and Low Tidal Volume Ventilation in Air Medical Transport Patients: The AIR-VENT Study. Respiratory Care, 2022, 67, 647-656.	0.8	1
353	A Persistent Left Lower Lobe Infiltrate and Chronic Cough Following Chest Wounds Sustained in Vietnam Twenty-Four Years Earlier. Military Medicine, 1993, 158, 499-500.	0.4	0
354	Prevention of Antibiotic Resistance in Hospitals. Annals of Internal Medicine, 2002, 136, 173.	2.0	0
355	Correctly scoring infections: CSI in the ICU*. Critical Care Medicine, 2007, 35, 2641-2643.	0.4	0
356	The Flood and Ebb of Septic Shock: Response. Chest, 2009, 136, 1705-1706.	0.4	0
357	Staphylococcal Pneumonia. , 0, , 444-454.		0
358	A magic bullet for sepsis: Getting back to the basics*. Critical Care Medicine, 2010, 38, 733-734.	0.4	0
359	Hospital-acquired pneumonia/ventilator-associated pneumonia prevention: Truth or dare!*. Critical Care Medicine, 2011, 39, 2015-2016.	0.4	0
360	1658C. difficile Recurrence is a Strong Predictor of 30-day Rehospitalization Among ICU Patients. Open Forum Infectious Diseases, 2014, 1, S443-S443.	0.4	0

#	Article	IF	Citations
361	881New Ventilator Associated Event (VAE) Definition: Persistence of Subjective Variability. Open Forum Infectious Diseases, 2014, 1, S253-S253.	0.4	0
362	Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival. Antimicrobial Agents and Chemotherapy, 2014, 58, 3581-3581.	1.4	0
363	The authors reply. Critical Care Medicine, 2016, 44, e231-e232.	0.4	0
364	The authors reply. Critical Care Medicine, 2016, 44, e50-e51.	0.4	0
365	The author replies. Critical Care Medicine, 2017, 45, e630-e631.	0.4	0
366	Reply to MacFadden et al. Clinical Infectious Diseases, 2018, 66, 479-480.	2.9	0
367	1008. Cluster Analysis to Define Distinct Clinical Phenotypes Among Septic Patients With Bloodstream Infections. Open Forum Infectious Diseases, 2018, 5, S300-S300.	0.4	0
368	2521 Use of forced air warming devices to induce fever-range hyperthermia in critically ill septic patients. Journal of Clinical and Translational Science, 2018, 2, 50-50.	0.3	0
369	1894. Antimicrobial Stewardship in the Intensive Care Unit: Survey of Critical Care and Infectious Diseases Physicians. Open Forum Infectious Diseases, 2018, 5, S543-S543.	0.4	0
370	872. PROPHETIC: Predicting Pneumonia in Hospitalized Patients in the ICUâ€"A Model and Scoring System. Open Forum Infectious Diseases, 2018, 5, S25-S25.	0.4	0
371	Redefining the Threshold for Broad-Spectrum Antibiotics. Annals of the American Thoracic Society, 2019, 16, 1367-1369.	1.5	0
372	Rebuttal From Drs AguilarÂand Kollef. Chest, 2019, 155, 668-669.	0.4	0
373	Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia â€“ Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 20-21.	4.6	0
374	Microbiologic Failure Despite Clinical Cure in Pneumonia: Cum Hoc and Post Hoc Ergo Propter Hoc. Clinical Infectious Diseases, 2020, 71, 3042-3043.	2.9	0
375	Prevention of nosocomial respiratory infections. , 2006, , 675-693.		0
376	Early Appropriate Empiric Therapy and Antimicrobial De-Escalation. Infectious Disease and Therapy, 2007, , 231-250.	0.0	0
377	2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP). Open Forum Infectious Diseases, 2019, 6, S760-S760.	0.4	0
378	1477. Impact Of Resistance Thresholds On Mortality In Hospital-Acquired And Ventilator-Associated Pneumonia. Open Forum Infectious Diseases, 2020, 7, S739-S740.	0.4	0

#	Article	IF	Citations
379	High levels of C-reactive protein and positive troponin T test results predicted 14-day mortality in unstable angina or non-Q-wave MI. ACP Journal Club, 1998, 129, 73.	0.1	0
380	Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia. Medicine (United States), 2022, 101, e29159.	0.4	0